As of 27 March 2024, Farmak AG has successfully finalized its acquisition of Symphar Sp. z o.o., becoming the sole owner of the Polish pharmaceutical company through a cash transaction.
The acquisition represents a part of Farmak’s international expansion strategy marking its latest M&A after last year’s acquisitions in the Czech Republic and Slovakia. It expands Farmak’s market share and strengthens its position in diabetology, psychiatry, neurology, women’s health and other segments in the EU. Management anticipates accelerated sales and profitability growth thanks to the synergies with the existing Polish operations acquired in 2016. An ambitious investment plan is in place to facilitate the further development of the company and further strengthening of relations with existing suppliers and other partners.
The transaction is a result of a thorough preparation and evaluation of different options in the Polish market. Symphar’s business and operations fully comply with the legal requirements and high ethical and corporate standards of Farmak. The closing took place after fulfilling the deal conditions and the relevant regulatory requirements.
Viktor Kostiuk, CEO at Farmak AG, commented:
“Today starts a new chapter for Farmak and Symphar. We’re looking forward to working with our new team members to grow our combined business and keep providing reliable treatments to patients and caregivers in Poland.”
About Farmak
Farmak, an international pharmaceutical company established in 1925, operates with a focus on research and development, manufacturing, and global sales and marketing of generics. With manufacturing and R&D facilities in Ukraine and Spain, Farmak has reached a strong presence globally. The company owns 10 commercial offices strategically positioned around the world, including Ukraine, Poland, the Czech Republic, Slovakia, Central Asia, the Asia Pacific region, the Middle East, and Western Europe. This extensive network underscores Farmak’s commitment to drive quality medicines worldwide.
About Symphar
Symphar is a Polish pharmaceutical company with its offices in Warsaw. Its team of 90 professionals works with more than 50 products in the diabetology, gynecology, psychiatry neurology and other therapeutic areas. In 2023, Symphar reached over EUR 22m revenue following its long-lasting period of stable and profitable growth.
Advisers
FinPoint investment banking firm has acted as the exclusive financial adviser to Farmak on the acquisition.
Swiss Merchant Corporation SA, a Swiss group specialized in private equity investments and M&A transactions, has acted as the exclusive financial adviser to the seller.
